Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes challenging immune and inflammatory phenomena. Though various therapeutic possibilities have been tested against coronavirus disease 2019 (COVID-19), the most adequate treatment has not yet been established. Propolis is a natural...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Biomedicine & pharmacotherapy 2021-06, Vol.138, p.111526-111526, Article 111526
Hauptverfasser:	Silveira, Marcelo Augusto Duarte, De Jong, David, Berretta, Andresa Aparecida, Galvão, Erica Batista dos Santos, Ribeiro, Juliana Caldas, Cerqueira-Silva, Thiago, Amorim, Thais Chaves, Conceição, Luis Filipe Miranda Rebelo da, Gomes, Marcel Miranda Dantas, Teixeira, Maurício Brito, Souza, Sergio Pinto de, Santos, Marcele Helena Celestino Alves dos, San Martin, Raissa Lanna Araújo, Silva, Márcio de Oliveira, Lírio, Monique, Moreno, Lis, Sampaio, Julio Cezar Miranda, Mendonça, Renata, Ultchak, Silviana Salles, Amorim, Fabio Santos, Ramos, João Gabriel Rosa, Batista, Paulo Benigno Pena, Guarda, Suzete Nascimento Farias da, Mendes, Ana Verena Almeida, Passos, Rogerio da Hora
Format:	Artikel
Sprache:	eng
Schlagworte:	ACE2 Anti-inflammatory agents Immunoregulation Original PAK1 blocker Propolis TMPRSS2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!